Search Results
Jan 12, 2026, 10:40 ET AMERICAN SKIN ASSOCIATION APPOINTS NEW BOARD MEMBER STEVEN A. ROSENBERG, MD, PHD
with metastatic melanoma and other advanced solid cancers. Dr. Rosenberg's laboratory also conducted the first human gene transfer experiments, a milestone in the development of gene therapy."I am delighted to welcome Dr. Rosenberg to our Board," said Howard P. Milstein, Chairman of ASA. "His
More news about: American Skin Association
Jan 12, 2026, 10:00 ET Basecamp Research launches world-first AI models for programmable gene insertion
thousands of untreatable diseases, potentially transforming millions of lives."Programmable Gene InsertionProgrammable gene insertion - placing large therapeutic DNA sequences at precise locations in the human genome - has been a central
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET Basecamp Research launches world-first AI models for programmable gene insertion
thousands of untreatable diseases, potentially transforming millions of lives."Programmable Gene InsertionProgrammable gene insertion - placing large therapeutic DNA sequences at precise locations in the human genome - has been a central
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET Basecamp Research bringt weltweit erste KI-Modelle für die programmierbare Gen-Insertion auf den Markt
um neue Medikamente zu entwickeln, gab heute die ersten KI-Modelle bekannt, die in der Lage sind, programmierbare Gene einzufügen, und damit eine neue Möglichkeit bieten, fehlerhafte Gene zu ersetzen und Zellen für therapeutische Zwecke umzuprogrammieren. Diese in Zusammenarbeit mit NVIDIA ausgebildeten
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET CytoReason unveils LINA, an AI Agent accelerated by NVIDIA for Pharma R&D, built on computational disease models
Together with collaboration partner Takeda, CytoReason published data at the United European Gastroenterology (UEG) Congress suggesting that TYK2-dependent gene signature enrichment is associated with both ulcerative colitis and Crohn's disease. These results provide an example of LINA's ability to generate
More news about: CytoReason
Jan 12, 2026, 10:00 ET Basecamp Research lance les premiers modèles d'IA pour l'insertion de gènes programmables
sites définis du génome humain, ouvrant ainsi une voie longtemps recherchée vers des traitements programmables.La plateforme AI-Programmable Gene Insertion (aiPGI™) de Basecamp Research est activée par EDEN, une nouvelle gamme de modèles d'IA évolutifs développés avec NVIDIA et ayant
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET Basecamp Research lança modelos de IA pioneiros no mundo para inserção programável de genes
inserções gênicas em locais definidos no genoma humano, abrindo um caminho há muito buscado para terapias programáveis.A plataforma AI-Programmable Gene Insertion (aiPGI™) da Basecamp Research é alimentada pela EDEN, uma nova família de modelos evolutivos de IA desenvolvida com a NVIDIA, treinada
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET Basecamp Research lanza los primeros modelos de IA del mundo para la inserción de genes programables
en sitios definidos del genoma humano, lo que abre un rumbo buscado por mucho tiempo hacia terapias programables.La plataforma AI-Programmable Gene Insertion (aiPGI™) de Basecamp Research está impulsada por EDEN, una nueva familia de modelos de IA evolutiva desarrollados con NVIDIA, formados
More news about: Basecamp Research
Jan 12, 2026, 08:03 ET BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations
Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced preliminary fourth quarter and full year 2025 unaudited revenue from continuing operations.
More news about: BioLife Solutions, Inc.
Jan 12, 2026, 08:00 ET Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
(lovotibeglogene autotemcel)LYFGENIA is a one-time ex-vivo lentiviral vector (LVV) gene addition therapy approved for eligible patients with sickle cell disease, in which a functional β-globin gene is added to patients' own hematopoietic (blood) stem and progenitor cells (HSPCs). This addition
More news about: Minaris Advanced Therapies
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
delayed menopause.5 TP53 is a well-recognized prognostic marker for EC; >50% of advanced or recurrent EC tumors are TP53wt (gene for tumor protein P53; wild-type), and ~40%-55% are both TP53wt and mismatch repair-proficient (pMMR).6-8 While immune checkpoint
More news about: Karyopharm Therapeutics Inc.
Jan 11, 2026, 15:00 ET REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
(DR)Sura-vec is being developed in collaboration with AbbVie, and could be the first gene therapy for a non-rare disease, if approved.Sura-vec is on track to be the first gene therapy for wet AMD. REGENXBIO expects top-line data from ATMOSPHERE® and ASCENT®
More news about: REGENXBIO Inc.
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
for KRAS, NRAS or BRAF genes based on circulating tumor DNA testing. Additionally, patients were required to have no amplification of the ERBB2/HER2 gene. In the RYBREVANT® and chemotherapy cohorts, patients were either treatment-naïve or had received at least one prior line in the metastatic
More news about: Johnson & Johnson
Jan 09, 2026, 10:00 ET Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
actionable gene fusions like NRG1.About BIZENGRI (zenocutuzumab-zbco)INDICATIONSBIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with
More news about: Partner Therapeutics, Inc.
Jan 09, 2026, 08:00 ET Averna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Jan. 9, 2026 /PRNewswire/ -- Averna Therapeutics, Inc., a biotechnology company developing novel genomic medicines based on gene insertion technology, today announced that Tom Barnes, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare
More news about: Averna Therapeutics
Jan 09, 2026, 08:00 ET Press Registration Is Now Open for the 2026 ACMG Annual Clinical Genetics Meeting
to experts at the forefront of medical and laboratory genetics, along with timely story ideas in areas such as artificial intelligence in genetics, gene editing, reproductive genetics, cancer genetics, direct-to-consumer genetic testing, exome sequencing, pre- and perinatal genetics, biochemical/metabolic
More news about: American College of Medical Genetics and Genomics
Jan 09, 2026, 07:30 ET Avista Therapeutics Expands AI Gene Therapy Platform to Break Barriers in the Delivery of Genetic Medicines
Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform. Through an AI-driven expansion of its capsid design program and
More news about: Avista Therapeutics
Jan 09, 2026, 07:00 ET Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
INS1201, an intrathecally-delivered gene therapy for patients with Duchenne muscular dystrophy (DMD).INS1202In December 2025, the Company opened the first clinical site for the Phase 1 ARMOR study of INS1202, an intrathecally-delivered gene therapy for patients with Amyotrophic
More news about: Insmed Incorporated
Jan 08, 2026, 16:46 ET QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Jan 08, 2026, 13:31 ET Akadeum Life Sciences to Highlight How Microbubbles Enable Rapid Cell Therapy Manufacturing for Larger Patient Populations at Biotech Showcase 2026
products, marking a key regulatory milestone for the platform. The DMF reflects Akadeum's adherence to stringent ancillary material standards for cell and gene therapy and alignment to FDA CMC guidance, enabling developers to confidently adopt Akadeum's
More news about: Akadeum Life Sciences
Jan 08, 2026, 12:00 ET The Board of Medicine Launches Membership Program Expanding Access to Emerging Medical Knowledge
Frontiers in Psychiatry: Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD; and
More news about: The Board of Medicine
Jan 08, 2026, 11:39 ET Bionova Scientific and Syenex Forge Strategic Alliance to Expand Access to High-Quality Plasmid DNA for Advanced Therapies
Syenex, a genetic medicines platform company. This partnership will expand global access to critical DNA plasmids for next-generation gene delivery for advanced cell and gene therapies.
More news about: Bionova Scientific
Jan 08, 2026, 11:00 ET SU2C DREAM TEAM TARGETS EARLY DETECTION OF GASTRIC CANCER
disease is more prevalent. The research will also include a special focus on people who have inherited genetic changes—including those in the CDH1 gene—that significantly increase their chances of developing diffuse gastric cancer, an aggressive subtype of the disease.The team's goal is to detect
More news about: Stand Up To Cancer
Jan 08, 2026, 10:05 ET The Roddenberry Foundation Recenters Exploration as the North Star for Learning
possibility. With enduring optimism, it invests in creative minds and bold ideas, pursuing a more humane and abundant future for all. Inspired by the legacy Gene Roddenberry began, the Foundation is the next generation's effort to bring the Roddenberry philosophy from script to form.
More news about: The Roddenberry Foundation
Jan 08, 2026, 10:00 ET GB Connections Completes Leadership Transition, Positioning the Business for Long-Term Stability and Customer Partnership
positions us for long-term success."This leadership evolution builds on the foundation established under longtime President and Head of Engineering, Gene Mannella, P.E., who continues to support the business in an advisory capacity as Chairman and Executive Technology Officer. His continued involvement
More news about: GB Connections LLC